Results: 5

Efficacy of tamsulosin versus tadalafil as medical expulsive therapy on stone expulsion in patients with distal ureteral stones: A randomized double-blind clinical trial

Int. braz. j. urol; 47 (5), 2021
ABSTRACT Purpose: To compare the effects of tadalafil, tamsulosin, and placebo as a medical expulsive therapy (MET) for distal ureteral calculi. Materials and Methods: This prospective randomized double-blind clinical trial was conducted on 132 renal colic patients with distal ureteric stones (≤1...

Tadalafil protector effect during ischemia-reperfusion in rats

Acta cir. bras; 32 (11), 2017
Abstract Purpose: To evaluate histological parameters in rat renal tissue after tadalafil use during hot ischemia for 45 minutes and reperfusion for 24 hours. Methods: Twenty rats were divided into 2 groups. In the experimental group 10 mg/kg of tadalafil was used per gavage before the procedure. All...

Tadalafil: protective action against the development of multiple organ failure syndrome

Abstract Introduction: Multiple organ failure syndrome (MOFS) is a pathology associated to unspecified and severe trauma, characterized by elevated morbidity and mortality. The complex inflammatory MOFS-related reactions generate important ischemia-reperfusion responses in the induction of this syndrome...

The effect of tadalafil therapy on kidney damage caused by sepsis in a polymicrobial septic model induced in rats: a biochemical and histopathological study

Int. braz. j. urol; 43 (2), 2017
ABSTRACT Introduction Sepsis is an inflammatory reaction to bacteria involving the whole body and is a significant cause of mortality and economic costs. The purpose of this research was to determine whether tadalafil exhibits a preventive effect on sepsis in a septic model induced in rats with cecal l...

Análisis de impacto presupuestal de las terapias combinadas bosentan + sildenafil, ambrisentan + tadalafil e iloprost + bosentan en pacientes diagnosticados con hipertensión pulmonar grupo 1 (HAPG1 idiopática-HAPI y asociada-HAPA) de clase funcional II, I
Budget impact analysis of the combination therapies bosentan + sildenafil, ambrisentan + tadalafil and iloprost + bosentan in patients diagnosed with pulmonary hypertension group 1 (idiopathic HAPG1-HAPI and associated-HAPA) functional class II, I

Tecnologías evaluadas: Nueva: ambrisentan (principal) + tadalafil (complementario) Nueva: iloprost (principal) + bosentan (complementario), Actual: bosentan (principal) + sildenafil (complementario). Población: Pacientes diagnosticados con hipertensión pulmonar grupo 1 (HAP idiopática-HAPI y asociad...